We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP37441
Abstract: FuGENE® SI provides researchers the following benefits when compared to other siRNA transfection reagents available:
-Improved gene silencing with lower siRNA amounts
-Decreased cellular toxicity
-Usage across a wide range of routine and difficult-to-transfect cell lines
-Quick and easy protocol
-Ability to co-transfect DNA
-Lower Costs
To demonstrate the utility and benefits of utilizing FuGENE® SI we present to you the following:
-Flexible and Rapid Transfection Protocol with FuGENE®SI: Allows researchers to seed cells and transfect the same day, perfect for high-throughput screening (HTS) applications
-FuGENE® SI Transfection reagent allows for highly efficient uptake of fluorescently labeled siRNAs
-Robust and gentle knockdown of overexpressed, green florescent protein in eukaryotic cell lines with minimal amounts of siRNAs delivered by FuGENE®SI
-Improved knockdown performance of FuGENE®SI vs. competitor reagent RNAiMax®in human breast cancer cell line
-Knockdown of endogenous FXYD1 in A549 with FuGENE® SI increases cell survival after treatment with antibody/drug conjugate (FXYD1/Cardiac Glycoside)
Summary: FuGENE SI is a novel, high-efficiency, non-toxic transfection reagent engineered for delivery of siRNA, miRNA, and other short RNAs into biologically relevant human and animal cells.
-Improved gene silencing with lower siRNA amounts
-Decreased cellular toxicity
-Usage across a wide range of routine and difficult-to-transfect cell lines
-Quick and easy protocol
-Ability to co-transfect DNA
-Lower Costs
To demonstrate the utility and benefits of utilizing FuGENE® SI we present to you the following:
-Flexible and Rapid Transfection Protocol with FuGENE®SI: Allows researchers to seed cells and transfect the same day, perfect for high-throughput screening (HTS) applications
-FuGENE® SI Transfection reagent allows for highly efficient uptake of fluorescently labeled siRNAs
-Robust and gentle knockdown of overexpressed, green florescent protein in eukaryotic cell lines with minimal amounts of siRNAs delivered by FuGENE®SI
-Improved knockdown performance of FuGENE®SI vs. competitor reagent RNAiMax®in human breast cancer cell line
-Knockdown of endogenous FXYD1 in A549 with FuGENE® SI increases cell survival after treatment with antibody/drug conjugate (FXYD1/Cardiac Glycoside)
Summary: FuGENE SI is a novel, high-efficiency, non-toxic transfection reagent engineered for delivery of siRNA, miRNA, and other short RNAs into biologically relevant human and animal cells.
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
CYTOCON as a tool to collect, compare and visualize available data on cells and cytokine concentrations in humans
Vlad Leonov, Ekaterina Mogilevskaia, Elita Gerasimuk, Nail Gizzatkulov, Oleg Demin
What can NMR do in the biopharmaceutical industry
Creative Proteomics
Proteomics Methods for Analysis of Post-Translational Modifications
Creative Proteomics
Proteomics is A Major New Technology for Drug Discovery
Creative Proteomics
How Can Proteomics Contribute to Microbial Research?
Creative Proteomics
